Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies Advancing Next-Generation ILD Therapies, analyses DelveInsight

DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory advancements.

The report offers extensive coverage of regulatory approvals, active and upcoming clinical trials, emerging drug candidates, novel mechanisms of action (MoAs), administration route trends, and key strategic developments that are anticipated to reshape ILD treatment paradigms in the coming years.

Request a free sample report: https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Global Momentum Toward Next-Generation Interstitial Lung Disease Treatments
According to DelveInsight's evaluation, the ILD pipeline is characterized by intense R&D activity led by major pharmaceutical and biotechnology companies, including AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Boehringer Ingelheim, Prometheus Biosciences, Bayer, Insmed, Roche, Ark Biosciences, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, Taiho Pharmaceutical, Syndax Pharmaceuticals, Galecto Biotech, CSL Behring, AstraZeneca, along with several emerging innovators.

These organizations are developing therapies that address fibrotic processes, inflammatory signaling, autoimmune mechanisms, immune system modulation, and tissue regeneration, underscoring the complex and multifactorial biology of ILD.

Access a free sample PDF for detailed therapeutic insights: https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Therapies Poised to Redefine the Interstitial Lung Disease Market
A broad and diverse set of investigational agents is advancing through various stages of clinical development. Noteworthy emerging Interstitial Lung Disease candidates include:
• AD-214
• Abatacept
• ATYR1923
• Inhaled Pirfenidone
• RO-0220912
• Lung stem cell-based therapies
• Bardoxolone methyl
• Pamrevlumab
• Deupirfenidone
• INOpulse
• OATD-01
• LT0011
• GDC-3280
• BI 1015550
• PRA023
• Yifenidone
• Riociguat
• Treprostinil Palmitil
• BMS 986278
• Zinpentraxin alfa
• LTI-03
• HZN-825
• ENV-101
• PLN-74809
• TAS-115
• Axatilimab
• GB0139
• CSL312
• Saracatinib
• and others
Spanning small molecules, biologics, cell-based, and gene-based therapies, these candidates are expected to meaningfully impact the Interstitial Lung Disease market by delivering more precise, effective, and patient-friendly treatment options.

Key Clinical Trial Milestones Shaping the Interstitial Lung Disease Pipeline
• February 2025: Boehringer Ingelheim reported positive Phase III results for its ILD therapy nerandomilast, supporting a potential second regulatory indication. Topline data from the FIBRONEER-ILD Phase III trial (NCT05321082) demonstrated improved lung function in patients with progressive fibrosing ILDs (excluding IPF). This success follows earlier positive outcomes in IPF, which formed the basis for a previously submitted NDA.
• March 2024: Boehringer Ingelheim initiated a randomized, double-blind, placebo-controlled clinical trial to evaluate BI 1015550 in patients with progressive fibrosing ILDs over a minimum duration of 52 weeks.
• April 2024: The company launched INTENSE, a prospective observational study examining the relationship between lung function decline and symptom progression in CTD-associated PF-ILD patients receiving nintedanib therapy.
• January 2024: aTyr Pharma commenced a proof-of-concept clinical trial assessing Efzofitimod in patients with systemic sclerosis-associated ILD (SSc-ILD).
The outcomes of these studies are expected to play a critical role in shaping future treatment strategies, regulatory pathways, and investment trends across the ILD landscape.

Further product-level details are included in the full report. Download the Interstitial Lung Disease Pipeline Report: https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Interstitial Lung Disease Overview: A Heterogeneous and Challenging Disorder
Interstitial Lung Disease encompasses a wide group of pulmonary conditions marked by chronic inflammation and progressive scarring of lung tissue, ultimately leading to impaired oxygen transfer. Common symptoms including shortness of breath, persistent cough, and fatigue-tend to worsen over time, significantly reducing quality of life.

Interstitial Lung Disease may result from several underlying factors, such as:
• Environmental and occupational exposures (e.g., asbestos, silica)
• Autoimmune disorders (e.g., rheumatoid arthritis, scleroderma)
• Medication-induced toxicity
• Genetic susceptibility

Diagnosis typically involves a combination of clinical assessment, high-resolution CT imaging, pulmonary function tests, and, in selected cases, lung biopsy. Current management strategies focus on reducing inflammation, slowing fibrosis, improving survival outcomes, and maintaining functional capacity.

With continued progress in biomarker discovery, targeted pathway research, and advanced inhalation technologies, the future of ILD treatment is becoming increasingly optimistic.

Route of Administration and Molecule Type Trends in the Interstitial Lung Disease Pipeline
DelveInsight categorizes Interstitial Lung Disease pipeline therapies by route of administration, including:
• Oral
• Intravenous
• Subcutaneous

Interstitial Lung Disease Pipeline assets are also segmented by molecular modality, such as:
• Small molecules
• Peptides
• Polymers
• Cell therapies
• Gene therapies
This wide therapeutic diversity reflects the industry's commitment to improving drug delivery, treatment adherence, and clinical effectiveness.

Interstitial Lung Disease Pipeline Assessment: Comprehensive Coverage
The Interstitial Lung Disease pipeline spans all phases of development, including:
• Late-stage (Phase III)
• Mid-stage (Phase II)
• Early-stage (Phase I)
• Preclinical and discovery programs
• Inactive and discontinued assets

Each Interstitial Lung Disease therapy is evaluated based on:
• Mechanism of action
• Biological targets
• Clinical efficacy and safety data
• Regulatory milestones
• Strategic collaborations and partnerships
• Molecular format
• Route of administration
The Interstitial Lung Disease pipeline report also analyzes licensing agreements, mergers and acquisitions, funding trends, and academic collaborations driving innovation in the ILD space.

Download the sample PDF for deeper insights: https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Interstitial Lung Disease Market Outlook: Growth Drivers, Challenges, and Unmet Needs
The global ILD market is expected to expand significantly due to several key factors.
Interstitial Lung Disease Market Growth Drivers
• Increasing global prevalence of fibrosing ILDs
• Wider clinical adoption of antifibrotic therapies
• Progress in precision medicine and inhaled treatment technologies
• Strong R&D investment and pipeline depth

Interstitial Lung Disease Market Challenges
• Delayed diagnosis and disease complexity
• High treatment costs associated with biologics and antifibrotics
• Limited long-term efficacy data for emerging therapies
• Variability in patient treatment response

Interstitial Lung Disease Unmet Needs
• Improved tools for early and accurate diagnosis
• Reliable disease-specific biomarkers
• Safer, better-tolerated long-term treatment options
• Precision therapies tailored to ILD subtypes

To explore detailed insights on ILD drugs, emerging therapies, and clinical advancements, Download the Sample PDF - Interstitial Lung Disease Pipeline Analysis: https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Information
Ankit Nigam
Manager - Marketing
info@delveinsight.com
+1-469-945-7679

About DelveInsight
DelveInsight is a leading business consulting and market research firm dedicated exclusively to the life sciences industry. The company delivers end-to-end intelligence solutions that support pharmaceutical and biotech organizations with actionable insights, strategic guidance, and data-driven decision-making. By combining deep therapeutic expertise with advanced analytics, DelveInsight helps clients accelerate growth, enhance operational efficiency, and strengthen their competitive edge within the global healthcare market.

This release was published on openPR.